Daniel Corbett, MD
Cornea and External Diseases Specialist · Tulsa, OKNPI 1225394232
Payments from drug & device makers
Across 103 payments — averaging $35.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$585
- Mallinckrodt Hospital Products Inc.$567
- Alcon$510
- Bausch & Lomb Americas Inc.$505
- Rxsight Inc$399
- Sun Pharmaceutical Industries Inc.$227
- plus $887 from 14 others
What the payments were for
- Food & beverage$3,58097%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 9 | $585 |
| Mallinckrodt Hospital Products Inc. | 19 | $567 |
| Alcon | 9 | $510 |
| Bausch & Lomb Americas Inc. | 17 | $505 |
| Rxsight Inc | 5 | $399 |
| Sun Pharmaceutical Industries Inc. | 12 | $227 |
| The Cameron-ehlen Group, Inc. | 2 | $142 |
| Shire North American Group Inc | 1 | $122 |
| AbbVie(2 entities) | 5 | $111 |
| Aerie Pharmaceuticals, Inc. | 5 | $91 |
| Harrow Eye, LLC | 3 | $89 |
| Mallinckrodt Enterprises LLC | 1 | $80 |
| Dompe US, Inc. | 4 | $70 |
| Oyster Point Pharma, Inc. | 4 | $56 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $36 |
| Biotissue Holdings Inc. | 1 | $27 |
| Tarsus Pharmaceuticals, Inc. | 1 | $25 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$360
- RXSIGHT CONTACT LENS$315
- RXSIGHT INJECTOR CARTRIDGE$315
- RXSIGHT INJECTOR HANDPIECE$315
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$315
- LIGHT ADJUSTABLE LENS (LAL)$315
- enVista MX60 IOL$240
- XIIDRA$228
- KXL System$176
- Photrexa$176
- AcrySof IQ PanOptix UV IOL$146
- AcrySof IQ VIVITY$146
- iDose$136
- Voyager DSLT$126
- Hydrus Microstent$126
- enVista Aspire IOL$120
- HEALON PRO$120
- Tecnis Simplicity$120
- Unity$117
- MIEBO$106
How this compares
Too few cornea and external diseases specialist providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 28 | $799,516 |
| XdemvyLotilaner | 32 | $63,849 |
| MieboPerfluorohexyloctane/Pf | 61 | $44,887 |
| RestasisCyclosporine | 48 | $36,565 |
| Prednisolone Acetate | 539 | $21,614 |
| TyrvayaVarenicline Tartrate | 21 | $14,652 |
| CequaCyclosporine | 12 | $10,427 |
| ValacyclovirValacyclovir Hcl | 185 | $8,159 |
| MoxifloxacinMoxifloxacin Hcl | 233 | $7,281 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $6,390 |
| Fluorometholone | 95 | $6,205 |
| LotemaxLoteprednol Etabonate | 16 | $5,155 |
| Loteprednol Etabonate | 22 | $3,708 |
| Latanoprost | 272 | $3,322 |
| Ketorolac Tromethamine | 125 | $3,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $70 | $799,51628 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $25 | $63,84932 claims |
| Bausch & Lomb Americas Inc.Miebo | $505 | $44,88761 claims |
| AbbVieRestasis | $111 | $36,56548 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $56 | $14,65221 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $227 | $10,42712 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Loteprednol Etabonate | $15 | $8,86338 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $91 | $6,39016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Tulsa
- Kamran RiazOklahoma City$238K
- David JacksonOklahoma City$5K
- Scott VadalaOklahoma City$2K
- Ahmad Abdel-AtyOklahoma City$1K
- Rhea SiatkowskiOklahoma City$534
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.